In-Clinic Evaluation of the MiniMed 670G System “Suspend Before Low” Feature in Children with Type 1 Diabetes

Abstract

In children aged 7-13 years with T1D, the "suspend before low" feature of the MiniMed 670G system demonstrated a hypoglycemia prevention rate of nearly 80% after exercise and did not involve rebound hyperglycemia. There were no events of severe hypoglycemia during the evaluation.